Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It was found that PAI1 expression was significantly higher in HCC than in adjacent liver tissues.
|
31640087 |
2020 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We documented higher serum PAI-1 in HCV-induced HCC than viral infection-free controls, but interestingly, lower than HCV-induced liver cirrhosis patients.This was not genotype related.
|
27459171 |
2016 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIF-2alpha-dependent PAI-1 induction contributes to angiogenesis in hepatocellular carcinoma.
|
25489981 |
2015 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CASE suppresses DEN-induced hepatocarcinogenesis by inhibiting fibrosis and PAI-1 mRNA transcription, suggesting its potential clinical application in preventing and treating human HCC.
|
24247078 |
2014 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated levels of plasminogen activator inhibitor-1 (SERPINE1/PAI-1) have been reported in patients with hepatocellular carcinoma (HCC) associated with viral infection.
|
22798504 |
2012 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, both rosiglitazone and pioglitazone significantly induced, whereas bezafibrate did not affect PAI-1 mRNA expression in the human liver carcinoma cell line HepG2.
|
21757225 |
2011 |
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results suggest that PAI-1 genotypes could be an important factor contributing to increased susceptibility and pathological development of HCC in Taiwanese population.
|
20706793 |
2010 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Protein expression in hepatoma HepG2 cells stimulated by TGF-beta(1) was analyzed by western blotting and plasminogen activator inhibitor type 1 (PAI-1) transcriptional activity in HepG2 cells was evaluated.
|
19793165 |
2010 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we examined whether adenoviral-mediated expression of a constitutively active form of FoxO1 (Ad-CA-FoxO1) inhibited insulin-stimulated PAI-1 expression in human HepG2 hepatocellular liver carcinoma cells and mouse AML12 hepatocytes.
|
19563779 |
2009 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of our study was to improve the detection of hepatocellular carcinoma (HCC) by measuring alfa-fetoprotein (AFP) in addition to other molecular markers by estimating the plasma levels of human catalytic fraction of reverse telomerase (hTERT) DNA, plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (t-PA) in 75 patients with liver desease.
|
18383849 |
2008 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cotransfection of human or rat PAI-1 promoter luciferase constructs with expression vectors for wild-type USF-2 or USF-2 mutants in human HepG2 and rat H4IIE cells as well as in primary rat hepatocytes revealed that the effects of USF on PAI-1 expression depend on the cell type rather than the promoter context and that the USF-specific region domain of USF accounts for the observed cell type-specific effects.
|
16330554 |
2006 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
In conclusion, distortion of autocrine TGF-beta signals in human HCC accelerates their malignant potential by enhancing cell growth as well as PAI-1 and VEGF production.
|
12700666 |
2003 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, distortion of autocrine TGF-beta signals in human HCC accelerates their malignant potential by enhancing cell growth as well as PAI-1 and VEGF production.
|
12700666 |
2003 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adhesion molecules (E-cadherin, catenins, serum intercellular adhesion molecule-1, CD44 variants), proteinases involved in the degradation of extracellular matrix (MMP-2, MMP-9, uPA, uPAR, PAI), as well as other molecules have been regarded as biomarkers for the malignant phenotype of HCC, and are related to prognosis and therapeutic outcomes.
|
12046056 |
2002 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The transcriptional induction of plasminogen activator inhibitor-1 and p21(WAF1/CIP1) by TGF-beta were detected in all HCC cell lines, implying that the molecular integrity of the TGF-beta receptors might be intact.
|
11906173 |
2002 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the role of PAI-1 in invasion and proliferation of hepatocellular carcinoma (HCC) cells, HLE cells were transfected with a vector capable of expressing an antisense PAI-1 transcript.
|
10470287 |
1999 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have analyzed the regulation of PAI-1 mRNA accumulation by interleukin (IL)-1, IL-6, and dexamethasone, known mediators of the acute phase response, in HepG2 cells, a highly differentiated human hepatoma cell line that produces a broad spectrum of acute phase proteins including PAI-1.
|
8034668 |
1994 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, these data clearly show that LRP is the major cell-surface receptor responsible for t-PA.PAI-1 complex binding and endocytosis on human hepatoma HepG2 cells and extend the multifunctional nature of LRP as an endocytosis receptor for several structurally and functionally distinct ligands.
|
8389767 |
1993 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hepatoma cell line Hep G2 has been shown to synthesize PAI-1 in response to insulin.
|
8387542 |
1993 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the current work we have analyzed the regulation of vitronectin by transforming growth factor-beta 1 (TGF beta 1) in this hepatoma cell line by Northern hybridization, polypeptide and immunoprecipitation analyses and compared the response to another TGF beta-regulated gene, plasminogen activator inhibitor (PAI-1).
|
1712727 |
1991 |